NeuroMetrix IPO To Help Build Direct Sales Of Neuropathy Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
NeuroMetrix will attempt to increase primary care physician adoption of its NC-stat neuropathy diagnostic system with the proceeds of an initial public offering of up to $34.5 mil. in stock
You may also be interested in...
NeuroMetrix
Nerve function testing firm is subpoenaed June 21 by the U.S. Justice Department in connection with an investigation of Neurometrix's sales and marketing practices for the NC-stat nerve conduction system, the company discloses June 25 in an SEC filing. NC-stat is made up of single-use biosensors, which accounted for almost 90% of the firm's $55 million in 2006 revenue, and data collection and analysis hardware and software designed to help physicians diagnose nerve diseases (1"The Gray Sheet" May 31, 2004, p. 29)...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.